Possibilities of cognitive-affective disorders correction in patients with atopic dermatitis using selank regulatory peptide

Objective: To evaluate the efficacy of the selank regulatory peptide against cognitive-affective disorders in patients with atopic dermatitis (AD).

Material and methods. The analysis of cognitive-affective disorders of 65 patients with atopic dermatitis (AD), randomized into 2 statistically comparable groups, was carried out. Patients of the first group received basic drug therapy (BT) for AD, the second group - a combination of selank and BT (S + BT) intranasally, 2 drops in each nasal passage, 3 times a day, for 14 days. The control group consisted of 30 healthy individuals. The levels of personal (LT) and reactive (RT) anxiety, alexithymia, the level of β-endorphin in the blood, and the quality of life (QOL) before treatment and after 30 days from its start were assessed.

Results. In patients with AD, the level of RT was 4.2 times higher than in the control group, RT - 3.2 times, alexithymia - 18 times. In the BT group, 30 days after the start of treatment, RT decreased 1.4 times and RT - 1.3 times. In the C+BT group, the decrease in LT and RT was equally significant - by 2.4 times. The levels of alexithymia and blood β-endorphin in the BT group did not change significantly. In the S+BT group, alexithymicity of patients decreased by 1.2 times, and the level of β-endorphin in the blood increased by 1.9 times. The quality of life index in the BT group decreased 1.2 times after 30 days from the start of therapy, and 1.7 times in the S + BT group.

Conclusion. Patients with AD are characterized by the increased levels of personal and reactive anxiety and alexithymia, which reduce their quality of life. The use of the selank regulatory peptide in the complex treatment of patients with AD has a corrective effect on affective-cognitive impairment, contributing to a decrease in the levels of personal and reactive anxiety, alexithymia, increases the level of β-endorphin in the blood and improves the quality of life of patients.

1. Будневский А.В., Слюсарев Е.А., Преображенский Ю.П. Алгоритмизация коррекции психосоматических соотношений при язвенной болезни. Прикладные информационные аспекты медицины. 2001;4(1):63-66

2. Бурлова Е.С. Роль коррекции психологических расстройств в динамике стенокардии напряжения у пожилых пациентов. Научно-медицинский вестник Центрального Черноземья. 2003;11:58-64

3. Ересько Д.Б., Исурина Г.С., Кайдановская Е.В., Карвасарский Б.Д., Карпова Э.Б., Смирнова Т.Г., Крылова Г.С., Тархан А.У. и др. Алекситимия и методы ее определения при пограничных психосоматических расстройствах: Методическое пособие. Санкт-Петербург, 1994. 15 с.

4. Кочергин Н.Г., Смирнова Л.М. Дерматологическое качество жизни как психосоматический симптом дерматоза. Российский журнал кожных и венерических болезней. 2006;4:11-15

5. Ханин Ю.Л. Краткое руководство к шкале реактивной и личностной тревожности Ч.Д. Спилбергера. Ленинград, 1976. 18 с.

6. Guo F., Yu Q., Liu Z., Zhang C., Li P., Xu Y., Zuo Y., Zhang G. et al. Evaluation of life quality, anxiety, and depression in patients with skin diseases. Medicine (Baltimore).2020;99(44):e22983. DOI: 10.1097/MD.0000000000022983

7. Hussain S., Ronaldson A., Arias de la Torre J., Sima R.M., Hatch S., Hotopf M., Dregan A. Depressive and anxiety symptomatology among people with asthma or atopic dermatitis: A population-based investigation using the UK Biobank data. Brain Behav Immun. 2020;90:138-144. DOI: 10.1016/j.bbi.2020.08.003

8. Jafferany M., Ferreira B.R., Abdelmaksoud A., Mkhoyan R. Management of psychocutaneous disorders: A practical approach for dermatologists. Dermatol Ther. 2020;4:e13969. DOI: 10.1111/dth.13969

9. Kage P., Zarnowski J., Simon J.C., Treudler R. Atopic dermatitis and psychosocial comorbidities - What's new? Allergol Select. 2020;4:86-96. DOI: 10.5414/ALX02174E

10. Kolik L.G., Nadorova A.V., Antipova T.A., Kruglov S.V., Kudrin V.S., Durnev A.D. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019;167(5):641-644. DOI: 10.1007/s10517-019-04588-9

11. Lio P.A., Wollenberg A., Thyssen J.P., Pierce E.J., Rueda M.J., DeLozier A.M., Terres J.A.R., Anderson P. et al. Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study. J Drugs Dermatol. 2020;19(10):943-948. DOI: 10.36849/JDD.2020.5422

12. Panikratova Y.R., Lebedeva I.S., Sokolov O.Y., Rumshiskaya A.D., Kupriyanov D.A., Kost N.V., Myasoedov N.F. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. DOI: 10.1134/S001249662001007X

13. Rønnstad A.T.M., Halling-Overgaard A.S., Hamann C.R., Skov L., Egeberg A., Thyssen J.P. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448-456.e30. DOI: 10.1016/j.jaad.2018.03.01

14. Silverberg J.I., Gelfand J.M., Margolis D.J., Boguniewicz M., Fonacier L., Grayson M.H., Ong P.Y., Chiesa Fuxench Z.C. et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol. 2019;181(3):554-565. DOI: 10.1111/bjd.17683

15. Willemsen R., Roseeuw D., Vanderlinden J. Alexithymia and dermatology: the state of the art. Int J Dermatol. 2008;47(9):903-910. DOI: 10.1111/j.1365-4632.2008.03726.x